化合物 T28775
中文名称 | 化合物 T28775 |
---|---|
中文同义词 | 化合物 T28775 |
英文名称 | Sibrafiban |
英文同义词 | Sibrafiban;Acetic acid, 2-[[1-[(2S)-2-[[4-[(Z)-amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-, ethyl ester;WBNUCLPUOSXSNJ-UHFFFAOYSA-N |
CAS号 | 172927-65-0 |
分子式 | C20H28N4O6 |
分子量 | 420.46 |
EINECS号 | |
相关类别 | |
Mol文件 | 172927-65-0.mol |
结构式 |
化合物 T28775 性质
密度 | 1.33±0.1 g/cm3(Predicted) |
---|---|
储存条件 | Store at -20°C |
溶解度 | DMSO:33.33 mg/mL(79.27 mM;需要超声波) |
形态 | 固体 |
酸度系数(pKa) | 13.16±0.10(Predicted) |
颜色 | 白色至米白色 |
Glycoprotein IIb/IIIa receptor
The effects of site occupancy by Sibrafiban on platelet activation are assessed using P-selectin expression, fibrinogen binding and microaggregate formation. Sibrafiban inhibits ADP and TRAP-stimulated fibrinogen binding and microaggregate formation in a concentration-dependent manner, whereas P-selectin expression is relatively unaltered. A decrease in site occupancy from peak to trough of Sibrafiban does not result in increased activation of platelets.
The effects of Ro 44-3888 on the platelet aggregation response to ADP (17 μmol) and on cutaneous bleeding times is determined in 8 rhesus monkeys given Sibrafiban 0.25 mg/kg/day or 0.5 mg/kg/day orally for 8 days. The maximum inhibition of ex vivo platelet aggregation and prolongation of bleeding time by Ro 44-3888 are dose dependent.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-10309 | Sibrafiban | 172927-65-0 | 5 mg | 3000元 |
2024/04/30 | HY-10309 | Sibrafiban | 10 mg | 4800元 |